Thursday, June 25, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

PARP Inhibition in the Management of Common Cancers


Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Gretchen Santos Fulgencio, MSN, FNP-BC
University of California, San Francisco
Berkeley, California

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Michael J Pishvaian, MD, PhD
Associate Professor
Department of Oncology
Director of the Gastrointestinal
Developmental Therapeutics
and Clinical Research Programs at
the NCR Kimmel Cancer Center at
Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, DC

Deborah Wright, MSN, APRN, CNS
Phase I Clinical Nurse Specialist
Oncology Infusion APP Team Lead
Stephenson Cancer Center
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Biologic rationale for the efficacy of PARP inhibitors, alone or in combination with other agents, in the treatment of diverse cancers; similarities and differences among approved and investigational PARP inhibitors
  • Frequency of germline BRCA mutations and other genomic alterations that confer sensitivity to PARP inhibitors in patients with ovarian, breast, prostate and pancreatic cancers; timing and types of testing approaches
  • Clinical benefits and tolerability of the approved PARP inhibitors olaparib, niraparib and rucaparib, alone or in combination with other agents, in front-line, recurrent and multiple regimen-relapsed ovarian cancer; selection of patients for PARP inhibitor therapy and incorporation into the treatment algorithm
  • Data supporting the FDA approvals of olaparib (OlympiAD trial) and talazoparib (EMBRACA trial) for patients with metastatic breast cancer with germline BRCA mutations; factors affecting sequencing with other therapies
  • Clinical implications of the pivotal Phase III POLO study evaluating maintenance olaparib for patients with metastatic pancreatic cancer with germline BRCA mutations after first-line platinum-based chemotherapy
  • FDA approval of rucaparib for patients with metastatic castration-resistant prostate cancer with deleterious BRCA mutations (germline and/or somatic) who have received androgen receptor-directed therapy and taxane-based chemotherapy; ongoing investigation of rucaparib in the Phase III TRITON3 trial
  • Results of the Phase III PROfound study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer; ongoing Phase III studies of niraparib (MAGNITUDE) and talazoparib (TALAPRO-2) in metastatic prostate cancer
  • Frequency, spectrum and severity of side effects associated with PARP inhibitors; class effects and unique toxicities; monitoring and management

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Comprehend how DNA damage repair pathway abnormalities can be exploited with PARP inhibition to elicit therapeutic benefit for patients with various cancers, including ovarian cancer, breast cancer, pancreatic adenocarcinoma and prostate cancer.
  • Understand the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
  • Assess available and emerging clinical trial data with and FDA indications for the various PARP inhibitors used for ovarian cancer, and develop strategies to identify patients for whom this approach might be appropriate.
  • Recognize the FDA-endorsed indications for the commercially available PARP inhibitors in the management of metastatic breast cancer, and discern how these agents can be optimally employed in nonresearch patient care.
  • Advise individuals with metastatic pancreatic adenocarcinoma found to harbor a germline BRCA mutation about recently presented clinical trial findings documenting the efficacy of PARP inhibitor maintenance therapy after first-line platinum-based chemotherapy.
  • Describe the rationale for testing patients with metastatic prostate cancer for BRCA1/2 or other related mutations, and advise appropriate individuals found to harbor these genetic abnormalities about available clinical research data documenting the efficacy of PARP inhibition.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Fulgencio and Ms Wright have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr AntonarakisConsulting Agreements: Amgen Inc, Astellas, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Other Remunerated Activities: Licensed patented technology to QIAGEN. Dr MooreAdvisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners. Dr O’ShaughnessyAdvisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc. Dr PishvaianConsulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Celgene Corporation, Foundation Medicine, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Merck, Merrimack Pharmaceuticals Inc, Perthera, Rafael Pharmaceuticals Inc, RenovoRx, Sirtex Medical Ltd; Contracted Research: AbbVie Inc, ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Curegenix, FibroGen, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Karyopharm Therapeutics, Lilly, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Ownership Interest: Perthera; Patent Pending: AbbVie Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.